Literature DB >> 11356987

Vascular adrenoceptors: an update.

S Guimarães1, D Moura.   

Abstract

The total and regional peripheral resistance and capacitance of the vascular system is regulated by the sympathetic nervous system, which influences the vasculature mainly through changes in the release of catecholamines from both the sympathetic nerve terminals and the adrenal medulla. The knowledge of the targets for noradrenaline and adrenaline, the main endogenous catecholamines mediating that influence, has recently been greatly expanded. From two types of adrenoceptors (alpha and beta), we have now nine subtypes (alpha1A, alpha1B, alpha1D, alpha2A/D, alpha2B, alpha2A/D, beta1, beta2, and beta3) and two other candidates (alpha1L and beta4), which may be conformational states of alpha1A and beta1-adrenoceptors, respectively. The vascular endothelium is now known to be more than a pure anatomical entity, which smoothly contacts the blood and forms a passive barrier against plasma lipids. Instead, the endothelium is an important organ possessing at least five different adrenoceptor subtypes (alpha2A/D, alpha2C, beta1, beta2, and beta3), which either directly or through the release of nitric oxide actively participate in the regulation of the vascular tone. The availability of transgenic models has resulted in a stepwise progression toward the identification of the role of each adrenoceptor subtype in the regulation of blood pressure and fine-tuning of blood supply to the different organs: alpha2A/D-adrenoceptors are involved in the central control of blood pressure; alpha1-(primarily) and alpha2B-adrenoceptors (secondarily) contribute to the peripheral regulation of vascular tone; and alpha2A/D- and alpha2C-adrenoceptors modulate transmitter release. The increased knowledge on the involvement of vascular adrenoceptors in many diseases like Raynaud's, scleroderma, several neurological degenerative diseases (familial amyloidotic polyneuropathy, Parkinson disease, multiple-system atrophy), some kinds of hypertension, etc., will contribute to new and better therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356987

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  177 in total

Review 1.  Brain, behavior, mental stress, and the neurocardiac interaction.

Authors:  Robert Soufer; James A Arrighi; Matthew M Burg
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Beta 2 adrenergic receptor 5' haplotypes influence promoter activity.

Authors:  Sharon E Johnatty; Maha Abdellatif; Lawrence Shimmin; Richard B Clark; Eric Boerwinkle
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 3.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

4.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

5.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

6.  Cyclic AMP-Rap1A signaling activates RhoA to induce α(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells.

Authors:  Selvi C Jeyaraj; Nicholas T Unger; Ali H Eid; Srabani Mitra; N Paul El-Dahdah; Lawrence A Quilliam; Nicholas A Flavahan; Maqsood A Chotani
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-23       Impact factor: 4.249

7.  Pro-inflammatory responses in human monocytes are beta1-adrenergic receptor subtype dependent.

Authors:  Laurel A Grisanti; Janel Evanson; Erica Marchus; Heather Jorissen; Andrew P Woster; Wanda DeKrey; Edward R Sauter; Colin K Combs; James E Porter
Journal:  Mol Immunol       Date:  2010-01-29       Impact factor: 4.407

8.  Alpha-dystrobrevin-1 recruits alpha-catulin to the alpha1D-adrenergic receptor/dystrophin-associated protein complex signalosome.

Authors:  John S Lyssand; Jennifer L Whiting; Kyung-Soon Lee; Ryan Kastl; Jennifer L Wacker; Michael R Bruchas; Mayumi Miyatake; Lorene K Langeberg; Charles Chavkin; John D Scott; Richard G Gardner; Marvin E Adams; Chris Hague
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

Review 9.  Antianginal actions of beta-adrenoceptor antagonists.

Authors:  Stephen T O'Rourke
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

10.  Why Not Life and Limb? Vasopressor Use in Intensive Care Unit Patients the Cause of Acute Limb Ischemia.

Authors:  Anastassia Newbury; Katharine D Harper; Arianna Trionfo; Frederick V Ramsey; Joseph J Thoder
Journal:  Hand (N Y)       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.